A phase 2 study to assess the safety and efficacy of FLX475 (tivumecirnon) combined with pembrolizumab in patients with advanced or metastatic gastric cancer

Category Systematic review
Conference2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, ASCO 2025
Year 2025
This article has no abstract
Epistemonikos ID: 967f4d112fc007a2e44adca7fbda99f0dd808972
First added on: Jan 22, 2026